WHO reports use of new malaria tools prevented millions of cases
According to reports, these WHO-recommended tools are increasingly being integrated into national healthcare systems. Since the approval of the first malaria vaccines in 2021, 24 countries have incorporated them into routine immunization schedules, as highlighted in the organization’s annual World Malaria Report.
Seasonal malaria chemoprevention has also seen significant growth, reaching 54 million children in 2024, compared with roughly 0.2 million in 2012.
Progress toward malaria elimination has continued steadily, with 47 countries and one territory officially recognized as malaria-free. Cabo Verde and Egypt received certification in 2024, while Georgia, Suriname, and Timor-Leste followed in 2025.
Despite these advances, the report estimated 282 million malaria cases and 610,000 deaths globally in 2024, representing an increase of about 9 million cases from the previous year. Approximately 95% of fatalities occurred in the WHO African Region, primarily among children under five years old.
"New tools for prevention of malaria are giving us new hope, but we still face significant challenges," WHO chief Tedros Adhanom Ghebreyesus said.
"Increasing numbers of cases and deaths, the growing threat of drug resistance, and the impact of funding cuts all threaten to roll back the progress we have made over the past two decades. However, none of these challenges is insurmountable."
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
